Editor’s Voice: October – time to get personal

Hannah Blake

pharmaphorum

Personalised medicine month in October brought a variety of different ideas, challenges and ethical issues to the table. Find out some of our personal highlights from this month, as well as what’s in store for November, December and early 2013 on pharmaphorum.

I suppose I should start by saying…. “Happy Halloween”!! While there were no ghosts or goblins on pharmaphorum this month, there was a variety of different experts sharing their thoughts on the newest pharma trend – personalised medicine.

For me, personalising treatments to an individual is a massive step for healthcare, which, for so many years, has been focusing on big blockbuster drugs for large patient populations. But now, more and more companies are starting to tap into small, niche, populations, and this new way of thinking is allowing the industry to learn, grow and evolve rapidly. Take a look below to find some top articles and interviews around this subject.

&nbsp,

“…personalising treatments to an individual is a massive step for healthcare…”

&nbsp,

Content highlights from October

October was truly fascinating in terms of content this month – while it was very hard to choose only a few, here are some of my personal highlights that you definitely shouldn’t miss…

• AstraZeneca’s Dr Bob Holland, shares his views on how personalised medicine will change the lives of patients.

• Find out why cancer therapy gets personal, in an article by Professor Paul Workman, from the UK Institute of Cancer Research.

• In a three-part interview, Kevin Hrusovsky from PerkinElmer talks to us about molecular interactions of disease, next generation sequencing and its role in personalised healthcare.

Ashish Rishi, Cetas Kinetic, discusses how this new era of medicine may expose a gap in medical education.

• We interview Isabelle Tanneau, ImmunID Technologies, about collaboration within personalised medicine – asking, is this the next step?

But we didn’t only feature great thought leadership from those within the personalised medicine field this month. Here are some other articles that are definitely worth a read:

• ‘Are global pharma brands worth the effort?’ discusses Ed Stapor, Havas Health – you can join in the debate here.

Gary Hendler of Eisai on the pharma company’s current pipeline and how its latest epilepsy drug, Fycompa, will be impacting on the lives of those with epilepsy.

&nbsp,

“…pharmaphorum’s Paul Tunnah, wonders whether pharma has something to learn from such risk takers who are willing to push the boundaries…”

&nbsp,

• Slightly still in awe of the recent record skydive from the stratosphere by Felix Baumgartner, pharmaphorum’s Paul Tunnah, wonders whether pharma has something to learn from such risk takers who are willing to push the boundaries in his latest “Tunnah’s musings”.

• pharmaphorum’s Rebecca Aris, interviews CME industry leader, Maureen Doyle-Scharff of Pfizer on how CME has changed and how it is evolving.

• Our ‘External perspectives’ series continues in an interview with AJ Brustein from Coca-Cola’s global brand team, who speaks with us about what pharma can learn from some of the company’s most recent campaigns.

Coming up on pharmaphorum

Tomorrow marks the first day of November, which for those in the UK will conjure up images of bonfires and toffee apples, while our friends in the US and rest of the world will be thinking towards Thanksgiving and other festivities. But on pharmaphorum, November will be all about marketing excellence.

What is marketing excellence? How do you know if your company is achieving marketing excellence? Which companies are already achieving marketing excellence? These questions, and more, will be answered throughout this month. We have pieces from GSK, Google, Boehringer Ingelheim, UCB Pharma, Eularis, IMS Health, Doctors.net and Astellas – that’s just to name a few!

And if you have any further questions, feel free to start a discussion on one of our social media channels, such as Facebook or Twitter, and we’ll point you in the right direction.

&nbsp,

“What is marketing excellence? How do you know if your company is achieving marketing excellence?”

&nbsp,

As the rest of 2012 has flown by at such a pace, we’re sure November will too. December is our partnerships &amp, licensing focus month, featuring thought leadership articles and interviews from big pharma, mid-size pharma, biotech and academia about what they each look for in a partnership.

Stay tuned to find out what we have in store for early 2013 – we’re currently finalising our editorial calendar and will have the first few topics ready to share shortly. If you’re interested in contributing in some way to pharmaphorum, please don’t hesitate to get in touch – we’re always welcome to new ideas!

So until next month, enjoy…

&nbsp,

pharmaphorum-social-media-workshop-22nd-November

&nbsp,

About the author:

Hannah joined pharmaphorum in early 2012, after graduating with a degree in Magazine Journalism &amp, Feature Writing in 2011, and leads our news coverage, in addition to liaising with new and existing feature authors. With over three years’ experience working within the journalism industry alongside university, Hannah has written for a number of different print and online publications, within the women’s lifestyle, travel and celebrity sectors. Now focussed on the pharma sector with her role at pharmaphorum, Hannah is embracing the challenges of working within a fast growing media organisation in this rapidly changing industry sector.

For any queries or contribution suggestions, please contact her here or via Twitter @Hannah_Blake2.

What would you like to see on pharmaphorum in 2013?